Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration

Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2015, Pages 317-327

  Shumaker, Robert ^a   Aluri, Jagadeesh ^a   Fan, Jean ^a   Martinez, Gresel ^a   Pentikis, Helen ^b   Ren, Min ^a  

^a EISAI INC   (United States)

^b SAJE Consulting LLC   (United States)

Author keywords

angiogenesis inhibitor; hepatic impairment; lenvatinib; pharmacokinetics; tyrosine kinase inhibitor

Indexed keywords

DIPHENHYDRAMINE; LENVATINIB; SERUM ALBUMIN; CARBANILAMIDE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; CHILD PUGH SCORE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; LIMIT OF QUANTITATION; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; OPEN STUDY; ORAL CLEARANCE; PARESTHESIA; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; RASH; RENAL CLEARANCE; SEVERE HEPATIC IMPAIRMENT; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; URINALYSIS; VITAL SIGN; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LIQUID CHROMATOGRAPHY; LIVER; LIVER DISEASES; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY; UNITED STATES; URINARY EXCRETION; URINE;

ADMINISTRATION, ORAL; ADULT; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENYLUREA COMPOUNDS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUINOLINES; RENAL ELIMINATION; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY; UNITED STATES;

EID: 84955181053     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.398     Document Type: Article

References (38)

1. Verheul HM, Voest EE, Schlingemann RO,. Are tumours angiogenesis-dependent? J Pathol. 2004; 202 (1): 5-13.
2. Dvorak HF,. Angiogenesis: update 2005. J Thromb Haemost. 2005; 3 (8): 1835-1842.
3. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med. 2003; 9 (6): 669-676.
4. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8 (8): 592-603.
5. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS,. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15 (3): 232-239.
6. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M,. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008; 14 (17): 5459-5465.
7. Matsui J, Yamamoto Y, Funahashi Y, et al., E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008; 122 (3): 664-671.
8. Boss DS, Glen H, Beijnen JH, et al., A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012; 106 (10): 1598-1604.
9. Yamada K, Yamamoto N, Yamada Y, et al., Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011; 17 (8): 2528-2537.
10. Sherman SI, Jarzab B, Cabanillas ME, et al., A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) [abstract]. J Clin Oncol. 2011: 5503.
11. Shumaker R, Aluri J, Fan J, Martinez G, Ren M, Chen K,. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E 7080) in healthy volunteers. Int J Clin Pharmacol Ther. 2014; 52 (4): 284-291.
12. Dubbelman AC, Rosing H, Mergui-Roelvink M, et al., A mass balance study of C-lenvatinib (E7080) in patients with advanced solid tumours or lymphomas [abstract]. Br J Clin Pharmacol. 2013; 76 (5): 831.
13. Inoue K, Asai N, Mizuo H, Fukuda K, Kusano K, Yoshimura T,. Unique metabolic pathway of [14C]lenvatinib after oral administration to male cynomolgus monkey. Drug Metab Dispos. 2012; 40 (4): 662-670.
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf Accessed March 25, 2014.
15. Dubbelman AC, Rosing H, Thijssen B, et al., Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 887-888: 25-34.
16. Gibaldi M, Perrier D,. Pharmacokinetics. New York, NY: Marcel Dekker, Inc.; 1975.
17. Jusko WJ,. Guidelines for collection of analysis of pharmacokinetic data. In:, Evans WE, Schentag JJ, Jusko WJ, eds., Applied Pharmacokinetics: Principles of Therapuetic Drug Monitoring. Vancouver, WA: Applied Therapeutics, Inc. 1992: 1-43.
18. Schuirmann DJ,. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15 (6): 657-680.
19. Widmer N, Decosterd LA, Leyvraz S, et al., Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer. 2008; 98 (10): 1633-1640.
20. Smith DA, Di L Kerns,. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010; 9 (12): 929-939.
21. Tortorici MA, Toh M, Rahavendran SV, et al., Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs. 2011; 29 (6): 1370-1380.
22. Inlyta (axitinib) tablets [prescribing information]. New York, NY: Pfizer; 2013.
23. Horak J, White J, Harris AL, et al., The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol. 2011; 68 (6): 1485-1495.
24. Iressa (gefitinib) tablets [summary of product characteristics]. Sodertalje, Sweden: AstraZeneca AB.
25. Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D,. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013; 71 (1): 123-132.
26. Bosulif (bosutinib) tablets [prescribing information]. New York, NY: Pfizer; 2013.
27. Yin OQ, Gallagher N, Tanaka C, et al., Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009; 31 (Pt 2): 2459-2469.
28. Tasigna (nilotinib) capsules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014.
29. Bello CL, Garrett M, Sherman L, Smeraglia J, Ryan B, Toh M,. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol. 2010; 66 (4): 699-707.
30. Sutent (sunitinib malate) capsules [prescribing information]. New York, NY: Pfizer; 2013.
31. LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al., Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012; 18 (10): 2954-2963.
32. Velcade (bortezomib) for injection [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2012.
33. Shibata SI, Chung V, Synold TW, et al., Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013; 19 (13): 3631-3639.
34. Votrient (pazopanib) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2013.
35. Ramanathan RK, Egorin MJ, Takimoto CH, et al., Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008; 26 (4): 563-569.
36. Gleevec (imatinib mesylate) tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013.
37. Miller AA, Murry DJ, Owzar K, et al., Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009; 27 (11): 1800-1805.
38. Nexavar (sorafenib) tablets [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2010.